SCHEMBL4766259

SCHEMBL4766259

CCN1CCN(c2nc(-c3ccc(CCCOCc4ccccc4)cn3)cc3ccccc23)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.41
KMT2A Q03164 4/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C19 P33261 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
ALDH1A1 P00352 3/20 0.39
PRMT5 O14744 1/20 0.39
HRH4 Q9H3N8 1/20 0.37
MAPT P10636 3/20 0.37
LMNA P02545 2/20 0.37
TSHR P16473 2/20 0.37
MEN1 O00255 3/20 0.37
NPC1 O15118 2/20 0.37
KDM4E B2RXH2 2/20 0.37
TP53 P04637 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HPGD P15428 2/20 0.36
GBA1 P04062 1/20 0.36
POLB P06746 1/20 0.36
HTT P42858 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771043 0.89 SMN1; SMN2 (0.41) SMN1; SMN2KMT2ACYP1A2CYP2C19L3MBTL1
Oxalic Acid SCHEMBL4770480 0.86 KDM4E (0.40) SMN1; SMN2KMT2ACYP1A2CYP2C19L3MBTL1
SCHEMBL4769464 0.86 SMN1; SMN2 (0.43) SMN1; SMN2KMT2ACYP1A2CYP2C19L3MBTL1
SCHEMBL4770557 0.85 SMN1; SMN2 (0.42) SMN1; SMN2KMT2ACYP1A2CYP2C19L3MBTL1
SCHEMBL4765280 0.82 PRMT5 (0.44) SMN1; SMN2KMT2ACYP1A2CYP2C19L3MBTL1
SCHEMBL4764073 0.82 SMN1; SMN2 (0.43) SMN1; SMN2KMT2ACYP1A2CYP2C19L3MBTL1
Hydrochloric Acid SCHEMBL4763997 0.81 ALDH1A1 (0.43) SMN1; SMN2KMT2ACYP1A2CYP2C19L3MBTL1
SCHEMBL4763853 0.79 PRMT5 (0.40) SMN1; SMN2KMT2ACYP1A2CYP2C19L3MBTL1
SCHEMBL4767242 0.78 HDAC3 (0.41) SMN1; SMN2KMT2ACYP1A2CYP2C19L3MBTL1
SCHEMBL4771319 0.78 SMN1; SMN2 (0.41) SMN1; SMN2KMT2ACYP1A2CYP2C19L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 SMN1; SMN2 27/4885KMT2A 1240/4885CYP1A2 2126/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 SMN1; SMN2 37/4885KMT2A 1300/4885CYP1A2 1489/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.